[Genetic Counselor]

Cascade testing is the process of offering genetic counseling and testing to the blood relatives of a person who has been found to carry a disease-causing genetic change. The first person in the family to be diagnosed is called the index patient. Once the exact genetic change in the index patient is known, relatives can be checked for that one specific change. The testing then “cascades” outward through the family: first to the closest relatives, and then, for anyone who also tests positive, on to their own close relatives.

The reason this matters is simple. You share part of your DNA with your parents, brothers and sisters, and children. If you carry a genetic change that raises the risk of a serious condition, some of them may carry it too, often without knowing. For many conditions, knowing early changes what happens next. A relative who carries a hereditary cancer gene change can begin earlier or more frequent screening. A relative with familial hypercholesterolemia, an inherited cause of very high cholesterol, can start treatment years before a heart attack. A couple who both carry beta-thalassemia can plan a pregnancy with full information.

The Centers for Disease Control and Prevention in the United States lists three groups of conditions where cascade testing has the strongest evidence of saving lives: hereditary breast and ovarian cancer (BRCA1 and BRCA2), Lynch syndrome (a hereditary colon and womb cancer condition), and familial hypercholesterolemia. But the same approach applies to many other conditions, including thalassemia, Duchenne muscular dystrophy, inherited heart rhythm and heart muscle conditions, and Fragile X syndrome.

Cascade testing is also efficient. An Indian study of beta-thalassemia families found that testing the relatives of affected children identified carriers at 5 to 6 times the rate of general population screening. Relatives of a known patient are simply much more likely to carry the same change than a random person.

Your doctor is not asking you to test your family. They are asking you to let your family know that an option exists, so each relative can decide for themselves.

[Genetic Counselor]

In general, cascade testing starts with first-degree relatives: parents, brothers and sisters, and children. Each of these relatives shares about half of your DNA. If a first-degree relative has died or cannot be reached, testing moves to second-degree relatives: grandparents, aunts and uncles, nieces and nephews, and half-siblings. When a relative tests positive, their own first-degree relatives are then offered testing, and so on through the family.

Exactly who is at risk depends on how the condition is inherited.
• Autosomal dominant conditions One copy of the changed gene is enough to raise risk. Examples include BRCA1 and BRCA2, Lynch syndrome, and familial hypercholesterolemia. Each child of a carrier has a 1-in-2 chance of inheriting the change, and each brother or sister usually has a 1-in-2 chance too. One side of the family usually carries it, and testing parents can show which side.
• Autosomal recessive conditions A person is affected only if they inherit a changed copy from both parents. Examples include beta-thalassemia, sickle cell disease, and spinal muscular atrophy. Both parents of an affected child are usually carriers. Each brother or sister of an affected child has a 2-in-3 chance of being a carrier if they are unaffected. Aunts, uncles, and cousins on both sides may also be carriers. For these families, cascade testing is mainly about identifying carriers before they plan their own pregnancies, and testing their partners.
• X-linked conditions The changed gene sits on the X chromosome. Examples include Duchenne muscular dystrophy and Fragile X syndrome. Females in the mother’s line, such as sisters, maternal aunts, and female cousins, may be carriers and can have affected sons. Their carrier status matters for pregnancy planning and, in some conditions, for their own health.

A genetic counselor will usually draw a family tree with you. This shows exactly which relatives are at risk, how high their chance is, and which order makes the most sense, including which relatives to prioritize because they are of an age where screening or prevention would already apply.

[Genetic Counselor]

Cascade testing is usually simpler, faster, and less expensive than the first test in the family. The index patient’s test often looked at many genes at once, searching for an unknown change. For a relative, the laboratory already knows exactly what to look for. It checks only that one specific change, at that one position in the DNA. This is called targeted or familial variant testing, and it can usually be done on a blood or saliva sample.

It helps if the relative’s laboratory has a copy of the index patient’s report, which names the gene and the exact change. Without it, the laboratory may need to run a much broader and costlier test.

• A positive result The relative carries the same genetic change. This does not mean they have the condition or will definitely develop it. It means they have the same increased risk as the index patient, and a doctor can advise on screening, prevention, or treatment. For carriers of a recessive condition, it means they are healthy but should consider partner testing before pregnancy.

• A negative result The relative does not carry the family’s genetic change. In most cases, this is a true negative: their risk for that condition returns to the same level as the general population. They usually do not need the extra screening that the rest of the family needs, and their children cannot inherit the change from them. This is often a very meaningful and reassuring result.

• An important limitation A negative targeted test only rules out the specific change already found in the family. It does not rule out other genetic changes. If a relative has a strong personal or family history on the other side of the family, a broader test may still be appropriate.

In a small number of families, the index patient’s result is a “variant of uncertain significance”, meaning the laboratory cannot yet say whether the change causes disease. Cascade testing is generally not recommended for these changes, because a result in a relative would not give a clear answer either.

A genetic counseling session before testing helps each relative understand what a positive or negative result would mean for them before they decide.

[Genetic Counselor]

This depends on whether knowing the result would change anything for the child during childhood. Professional guidelines, including those from the American Society of Human Genetics and the European Society of Human Genetics, follow one main principle: test children when there is a medical benefit in childhood, and otherwise wait until they can make their own choice.

• Conditions where childhood testing is recommended Some conditions need screening or treatment in childhood. Familial hypercholesterolemia is the clearest example. The European Atherosclerosis Society recommends testing children from around 5 years of age and, for those affected, starting cholesterol-lowering medication from around 8 to 10 years of age. Starting early lowers the total cholesterol exposure over a lifetime and greatly reduces the risk of early heart disease. Familial adenomatous polyposis, a hereditary condition that causes hundreds of bowel polyps, is another example, since bowel checks usually begin around 10 to 12 years of age. Some inherited heart rhythm conditions also fall into this group.
• Adult-onset conditions For conditions such as BRCA1, BRCA2, and Lynch syndrome, screening does not usually start until adulthood. Guidelines generally recommend waiting until the child is an adult and can decide for themselves. This protects the child’s own right to choose whether they want this information, and when.
• Carrier status for recessive or X-linked conditions Being a carrier of beta-thalassemia or Duchenne muscular dystrophy does not affect a child’s own health in most cases, but it matters for their future pregnancies. Carrier testing is usually offered in the late teenage years or adulthood, ideally before marriage or pregnancy planning, when the young person can take part in the decision.

Parents often feel a strong urge to “just know”. That feeling is completely understandable. A genetic counselor can talk through the timing that fits your family’s condition, your child’s age and maturity, and what the result would change.

[Genetic Counselor]

Telling relatives is often the hardest part. Research shows that many at-risk relatives are never tested. A 2022 review combining many studies of hereditary cancer families found that when patients were left to inform relatives on their own, only about 36 in every 100 relatives went on to have testing. When the medical team contacted relatives directly, with the patient’s permission, this rose to about 58 in every 100. Similar gaps have been seen for inherited heart conditions.

In India, family and social concerns add further barriers. A 2025 study of families with transfusion-dependent thalassemia found that only about 16 in every 100 eligible extended relatives had been screened, even though more than a third of those screened turned out to be carriers. Fear of stigma, particularly around marriage prospects, was the main reason families hesitated to share.

Some practical steps that help:
• Use a family letter Many genetics clinics provide a written letter explaining the condition, the gene change, and how to get tested. Studies show written information aids improve testing rates. Relatives can take it straight to their own doctor.
• Share the actual report Give relatives a copy of your genetic test report, or the gene name and exact change. This makes their testing faster, cheaper, and more accurate.
• Start with those at highest risk Begin with brothers, sisters, parents, and adult children. They can then share with their own families.
• Ask your clinic for help Some genetics services can contact relatives directly, with your consent, or offer a joint counseling session for the family.

Some relatives may choose not to be tested, and that is their right. The goal is to make sure they have the information, not to pressure a decision. Remember that a negative result can bring real relief to many relatives. Genetic counseling services in India are increasingly available through hospital genetics departments and accredited laboratories, and many offer counseling for relatives remotely.

[Genetic Counselor]

Beta-thalassemia is a genetic condition in which the body cannot make enough of a protein called beta-globin, one of the building blocks of haemoglobin, the molecule inside red blood cells that carries oxygen throughout the body. Without enough beta-globin, red blood cells cannot be built or maintained properly, and this leads to anaemia — a shortage of healthy red blood cells — that can range from barely noticeable to severe and life-threatening depending on how much beta-globin the body can still make.

Haemoglobin is normally made of two different protein chains working together in a balanced pair: two alpha-globin chains and two beta-globin chains. The instructions for building the beta-globin chain come from a single gene called HBB. When a person has a pathogenic variant, meaning a harmful change, in one or both copies of the HBB gene, the body produces too little beta-globin, or none at all. This creates an imbalance: the alpha-globin chains, which are still being made normally, have no matching partner and begin to clump together inside developing red blood cells. These clumps damage the red blood cells from the inside, causing many of them to die before they even leave the bone marrow, a process called ineffective erythropoiesis, and causing the ones that do reach the bloodstream to break down early, a process called haemolysis. The bone marrow responds by working harder and expanding, which is why more severely affected individuals can develop broadening of the facial and skull bones over time if the condition goes untreated.

How much beta-globin a person can still make depends on which HBB variant they carry. A variant that stops beta-globin production completely is called a beta-zero variant, while one that allows some reduced production is called a beta-plus variant. The combination of variants a person inherits — for example, two beta-zero variants versus one beta-zero and one beta-plus — is a major reason why beta-thalassemia ranges from a mild, often unnoticed trait to a severe, transfusion-dependent condition, which is described further below.

Beta-thalassemia is not caused by anything a parent did during pregnancy, and it cannot be caught from another person or spread through contact. It comes entirely from the specific combination of HBB gene copies a child inherits from each parent.

[Genetic Counselor]

Beta-thalassemia is generally grouped into three levels of severity, and the level a person falls into depends on how much functional beta-globin their particular combination of HBB variants still allows.

• Beta-thalassemia major, also called Cooley’s anaemia. This is the most severe form, usually noticed between six and twenty-four months of age as the protective haemoglobin present at birth naturally declines. Affected infants develop pale skin from severe anaemia, poor weight gain, slowed growth, mild yellowing of the skin and eyes called jaundice, and an enlarged liver and spleen as these organs try to compensate for the shortage of healthy red blood cells. Without regular treatment, bone changes from marrow expansion and severe, life-threatening anaemia follow.
• Beta-thalassemia intermedia. This form causes a more variable, generally milder anaemia that does not require regular transfusions in early childhood, though needs can increase later in life. Individuals may still develop jaundice, gallstones, slow-healing leg ulcers, bone deformities, an enlarged spleen, and, over time, elevated blood pressure in the lungs called pulmonary hypertension.
• Beta-thalassemia trait, also called beta-thalassemia minor. This describes carriers, who have one altered and one working copy of the HBB gene. Most carriers have no symptoms at all and are unaware of their status until tested, though some have a very mild anaemia.

Diagnosis usually begins with a complete blood count, which typically shows small, pale red blood cells and anaemia of a severity that fits the person’s symptoms. A close look at the blood under a microscope often shows red blood cells of unusual shapes and sizes. Because this pattern can look similar to iron-deficiency anaemia, which is also common in India, a haemoglobin analysis test — either haemoglobin electrophoresis or high-performance liquid chromatography (HPLC) — is essential to tell the two apart and confirm beta-thalassemia. This test measures the different types of haemoglobin in the blood and typically shows reduced or absent normal adult haemoglobin along with elevated levels of two other forms, haemoglobin A2 and hemoglobin F, in beta-thalassemia. Genetic testing of the HBB gene then confirms the diagnosis, identifies the exact variants involved, and is an important step before testing other family members or planning future pregnancies, discussed next. It is worth noting that thalassemia trait is sometimes mistaken for iron deficiency and treated with iron supplements unnecessarily, so confirming the correct diagnosis with iron studies and haemoglobin analysis matters for appropriate care.

[Genetic Counselor]

Yes, beta-thalassemia is inherited in an autosomal recessive pattern, meaning a person needs a change in both of their two copies of the HBB gene — one inherited from each parent — to have the disease itself.

A person who inherits an altered copy from only one parent is called a carrier, or is said to have beta-thalassemia trait. Carriers generally have no symptoms and often do not know their status unless tested, but they can pass the altered gene copy on to their own children. When both parents of a child are carriers, each pregnancy carries a 1-in-4 chance of a child inheriting two altered copies and having beta-thalassemia, a 1-in-2 chance of a child inheriting one altered copy and being a carrier like the parents, and a 1-in-4 chance of a child inheriting two working copies and being unaffected. Whether a child who inherits two altered copies develops beta-thalassemia major or the milder intermedia form depends on the specific combination of variants involved, since some allow more residual beta-globin production than others, as explained above.

Beta-thalassemia carrier frequency is notably high across India, with an average of around 3 to 4 percent of the population carrying an altered HBB gene copy, and some communities showing carrier frequencies of 8 percent or higher. This adds up to tens of millions of carriers nationally, and an estimated 10,000 to 15,000 infants are born with beta-thalassemia major in India each year. Because of this high background carrier rate, testing is recommended not only for the parents and siblings of someone diagnosed with beta-thalassemia, but more broadly for couples planning a pregnancy, particularly given that several Indian states now require or strongly encourage premarital or antenatal thalassemia screening. A simple blood test can identify carriers even before a couple has an affected child.

For couples who are both carriers, options include prenatal diagnosis once the family’s specific HBB variants are known — testing a pregnancy through chorionic villus sampling or amniocentesis — and preimplantation genetic testing performed alongside in vitro fertilization, which allows embryos to be tested before a pregnancy begins. A genetic counselor can walk a family through these options in the context of their specific variants and preferences.

[Genetic Counselor]

Treatment for beta-thalassemia depends heavily on severity, ranging from no treatment at all for most carriers to intensive, lifelong care for beta-thalassemia major.

• Regular blood transfusions. For beta-thalassemia major, transfusions every two to five weeks are the foundation of treatment, keeping haemoglobin high enough to support normal growth and development and to suppress the overactive, damaging bone marrow response described earlier. Some individuals with beta-thalassemia intermedia also need transfusions occasionally, such as during illness, surgery, or pregnancy.
• Iron chelation therapy. Regular transfusions, and in intermedia even increased absorption of iron from food, cause iron to build up in the heart, liver, and hormone-producing glands over years, which can be life-threatening if untreated. Medications called iron chelators bind this excess iron so the body can remove it, and are essential alongside transfusion therapy. Options include an injectable medication, deferoxamine, and two oral medications, deferiprone and deferasirox, chosen based on individual response, organ involvement, and tolerability.
• Luspatercept. This newer injectable medication helps red blood cells mature more effectively in the bone marrow, and has been shown to meaningfully reduce transfusion needs in some individuals with transfusion-dependent beta-thalassemia.
• Mitapivat. An oral medication that activates an enzyme called pyruvate kinase to support healthier red blood cell function, studied both in individuals who need regular transfusions and those who do not.
• Folic acid supplementation. Commonly given to support the bone marrow’s increased demand for building blocks to make red blood cells.
• Splenectomy, or surgical removal of the spleen, may be considered when the spleen enlarges significantly and is driving up transfusion requirements, though it is generally delayed as long as possible because it raises long-term infection risk.
• Hematopoietic stem cell transplantation. This remains the only established cure for beta-thalassemia, replacing the affected bone marrow with healthy stem cells, usually from a matched sibling donor. Outcomes are best when performed at a younger age, before iron overload and organ damage have accumulated, and several centres in India have experience performing this transplant for beta-thalassemia.
• Gene therapy. The newest treatment approach modifies a person’s own stem cells, either by adding a working copy of a beta-globin gene or by switching on the body’s fetal form of haemoglobin, so that transfusions are no longer needed. Two such therapies, betibeglogene autotemcel and exagamglogene autotemcel, have shown that the large majority of treated individuals no longer need regular transfusions afterward, and are approved in some countries, though availability, cost, and infrastructure currently limit access to this treatment in India.

Care for beta-thalassemia major or intermedia is generally best coordinated through a haematologist experienced in thalassemia, working alongside specialists for the heart, hormone system, and bones as needed, since the condition and its treatments affect multiple organ systems over a lifetime.

[Genetic Counselor]

The outlook for beta-thalassemia has improved enormously over recent decades and now depends heavily on consistent access to transfusion and iron chelation therapy. Individuals with beta-thalassemia major who receive regular transfusions together with effective iron chelation from early childhood onward can now expect to live well into adulthood, with many reaching their fifties and beyond, compared to a childhood-limited lifespan before modern chelation became widely available. The most important factor affecting long-term health is how well iron overload is controlled, since untreated iron buildup in the heart is the leading cause of serious complications. Beta-thalassemia intermedia follows a more variable course depending on how much transfusion support a person eventually needs, and beta-thalassemia trait carries a normal life expectancy with no disease-related monitoring needed beyond awareness for family planning purposes.

Because beta-thalassemia major and intermedia affect several organ systems over time, regular monitoring is recommended throughout life:
• Blood counts and transfusion response. Checked regularly, typically every two to five weeks alongside each transfusion, to confirm treatment is keeping haemoglobin at a healthy, stable level.
• Iron overload. Blood ferritin levels are checked roughly every three months as a general indicator, but because ferritin alone can be misleading, a specialized magnetic resonance imaging scan of the heart and liver is recommended at least once a year to measure the actual amount of iron stored in these organs and guide chelation dosing.
• Heart function. Regular heart evaluations, including echocardiograms, are recommended given that iron-related heart damage has historically been the leading cause of death in undertreated beta-thalassemia.
• Growth, puberty, and hormone function. Iron can also build up in glands that control growth, puberty, and blood sugar, so annual monitoring of growth, pubertal development, thyroid function, and blood sugar is recommended, particularly through childhood and adolescence.
• Bone health. Bone density testing along with adequate vitamin D and calcium intake is recommended, since thinning bones are common in beta-thalassemia major.
• Infection precautions after splenectomy. Individuals who have had their spleen removed need specific vaccinations and should seek prompt medical care for any fever, since the spleen normally plays an important role in fighting certain infections.

With consistent, coordinated care, many of the serious complications of beta-thalassemia can be prevented or significantly delayed, which is why staying connected to a treatment centre experienced in thalassemia care makes a meaningful difference over a person’s lifetime. Consultation with a geneticist is advised to tailor a care recommended to your health.

[Genetic Counselor]

Because whole genome sequencing reads virtually the entire genetic code rather than only the coding exome, it can pick up several categories of genetic change that whole exome sequencing is not designed to see well:

• Structural rearrangements, such as inversions, where a segment of a chromosome is flipped or repositioned without any genetic material actually being gained or lost. Whole exome sequencing reads short, disconnected stretches of coding DNA, which makes it poorly suited to recognizing this kind of large-scale rearrangement. Whole genome sequencing reads DNA in a far more continuous way, which makes it considerably better at catching changes like this.
• Disease-causing changes in the regulatory and splicing-relevant regions that surround genes. Not every disease-causing change lies within the stretch of DNA that is directly translated into protein; some sit in nearby regions that act as switches, controlling when and how strongly a gene is used, or that control how a gene’s instructions are correctly edited together. Because whole exome sequencing does not read these surrounding regions at all, a change located there is simply invisible to it.
• Certain repeat expansion disorders. A number of genetic conditions are caused not by a single altered letter but by a short sequence of letters that repeats far more times than it normally should, a pattern that whole exome sequencing’s capture-based approach is not well suited to detecting reliably.
• At least some information from the mitochondrial genome, the small, separate set of genetic instructions carried inside mitochondria, the structures that produce energy for the cell. Because whole exome sequencing’s capture step targets only coding DNA within the cell’s main genetic material, it generally does not capture mitochondrial sequence at all, while whole genome sequencing, reading DNA more broadly, can pick up at least some of this information as a byproduct.

These advantages come with practical trade-offs. Detecting a mitochondrial change present in only a small fraction of a person’s cells, a situation called heteroplasmy, at very low levels can still require dedicated mitochondrial-specific testing performed at much greater depth than a standard whole genome sequencing run provides, and a larger volume of data overall means more findings of every kind, including ones that take longer to classify. A geneticist weighs whether these specific categories of genetic change are plausible enough in a given family’s situation to justify choosing whole genome sequencing over the narrower, generally faster and less expensive whole exome sequencing.

[Genetic Counselor]

Every cell in the body carries a complete set of genetic instructions, written in a long molecule called DNA, that runs to roughly three billion individual chemical letters. Only a small slice of this, called the exome, is actually translated into the proteins that build and run the body; the rest, sometimes loosely called “non-coding” DNA, was once assumed to be filler but is now known to contain the switches, signals, and structural elements that control when and how genes are turned on. Whole genome sequencing is a laboratory test that reads essentially this entire three-billion-letter sequence at once, rather than reading only the coding exome, as whole exome sequencing does, or a handful of chosen genes, as a gene panel does.

A doctor recommends whole genome sequencing in a few specific situations. It is increasingly used as a first-tier test for critically ill infants and children, particularly in intensive care, where a fast, comprehensive answer can directly change urgent treatment decisions. It is also recommended when a person’s symptoms strongly suggest a genetic cause but whole exome sequencing has already been performed and did not provide an answer, since a meaningful share of genetic conditions are caused by changes that lie outside the coding exome altogether. In some centers, particularly where cost and turnaround time allow, it is offered as a first-line broad test in place of whole exome sequencing, since it can be reanalyzed for a wider range of causes later without needing to draw a new sample.

It is worth understanding from the outset that whole genome sequencing, like other forms of genetic testing, is a diagnostic tool rather than a guarantee of an answer. A clear genetic explanation is found in a meaningful proportion of cases, discussed further below, but many families will not receive a definitive result on a first attempt, and the sheer volume of information this test produces means that interpretation depends heavily on the experience of the genetics team reviewing it. A geneticist or genetic counselor is generally involved both before testing, to set realistic expectations, and after, to explain what the result actually means.

[Genetic Counselor]

To perform whole genome sequencing, a laboratory first extracts DNA from a blood or saliva sample and breaks it into millions of small, overlapping fragments. Unlike whole exome sequencing, this process skips the “capture” step in which chemical probes fish out only the coding fragments; instead, essentially all of the fragments, coding and non-coding alike, are read directly by a sequencing machine, which determines the exact order of the four chemical building blocks, represented by the letters A, T, C, and G, that make up each one. Because each stretch of the genetic code is typically read several times over from different overlapping fragments, a computer can piece the fragments back together and compare the result to a standard reference sequence, flagging places where a person’s genetic code differs from what is typically expected. Those differences, called variants, are then filtered and reviewed by geneticists to decide which, if any, explain the person’s symptoms.

Skipping the capture step is what sets whole genome sequencing apart from its two closest relatives. Whole exome sequencing uses that capture step to focus exclusively on the coding exome, which makes up only about 1 to 2 percent of the total genetic code; this keeps the volume of data far smaller and the cost lower, but it means the test is blind to the roughly 98 percent of the genetic code lying outside the exome, including the regulatory switches that control genes, deep intronic regions, and many kinds of structural rearrangements. Chromosomal microarray, a different technology altogether, does not read the sequence of DNA letters at all; it instead measures the amount of genetic material present across the genome, which makes it well suited to detecting a missing or extra stretch of DNA but blind to a single altered letter within a gene.

Because it reads virtually everything, whole genome sequencing can detect several categories of genetic change that whole exome sequencing is not designed to see well: structural rearrangements such as inversions, disease-causing changes in regulatory and splicing-relevant regions outside the exome, certain repeat expansion disorders, and, because it is not limited by capture probes, at least some sequence from the small separate genome carried inside mitochondria, the cell’s energy-producing structures. This last point comes with a caveat: detecting mitochondrial changes present in only a small fraction of a person’s cells, a situation called heteroplasmy, at very low levels can still require dedicated mitochondrial-specific testing performed at much greater depth than a standard whole genome sequencing run provides.

[Genetic Counselor]

When whole genome sequencing identifies a change in a gene that is already well understood and clearly matches a person’s symptoms, the finding is highly reliable. Across a recent meta-analysis pooling multiple clinical studies, whole genome sequencing identified a genetic cause in roughly 3-in-10 previously undiagnosed individuals overall, compared with a little over 2-in-10 for whole exome sequencing; this overall difference was described as a modest advantage that did not reach statistical significance, meaning it could reflect chance in some of the pooled studies. The advantage was clearer, however, within specific clinical groups: among critically ill patients, whole genome sequencing identified a cause in close to 4-in-10 cases compared with roughly 3-in-10 for whole exome sequencing; among those with neurologic conditions, the gap widened further, to nearly 6-in-10 compared with 4-in-10; and among those with multiple congenital anomalies, roughly 5-in-10 compared with under 4-in-10. Among people who did receive a positive diagnosis, whole genome sequencing and whole exome sequencing were similarly likely, at roughly 6-in-10 and 5-in-10 respectively, to change medical management in some way. Families should understand, even so, that more than half of those tested with either approach will not receive a definitive genetic answer on a first round of testing.

A second important limitation, shared with whole exome sequencing, is the variant of uncertain significance: a genuine, confirmed genetic change for which there is not yet enough scientific evidence to say whether it causes disease or is harmless variation. Because whole genome sequencing reads far more of the genetic code than any other clinical test, this kind of ambiguous finding is common, and a geneticist will explain clearly when a reported finding falls into this uncertain category rather than being a confirmed cause; classifications are regularly revisited as scientific understanding grows.

Whole genome sequencing can also uncover secondary findings: genuine, medically significant findings unrelated to the original reason for testing, such as a gene linked to a treatable heart condition or a hereditary cancer risk. The American College of Medical Genetics and Genomics maintains a specific list, currently covering 84 genes where early knowledge is considered to change medical management, and families are always given the choice, discussed during pre-test counseling, of whether they wish to receive this kind of unrelated information at all.

Finally, whole genome sequencing has its own technical blind spots. Short-read sequencing, the technology used by most clinical laboratories today, still struggles with certain highly repetitive stretches of the genome, cannot reliably detect very low-level mosaic changes present in only a small fraction of a person’s cells, and does not capture chemical modifications to DNA that affect gene activity without changing the underlying sequence. Newer long-read sequencing technologies are beginning to address some of these gaps but are not yet standard in most clinical settings.

[Genetic Counselor]

A whole genome sequencing result is generally reported in one of three ways: a genetic cause was clearly identified and explains the person’s symptoms; one or more variants of uncertain significance were found, meaning a real change exists but its significance is not yet clear; or no relevant genetic change was identified despite the breadth of the search. What happens next depends on which of these applies:

• When a clear genetic cause is found, a geneticist or genetic counselor explains what the finding means for the person’s health and, where relevant, connects the family with specialists for ongoing management, along with discussing the chance of the condition recurring in future pregnancies or affecting other relatives.
• When a variant of uncertain significance is found, testing close relatives can sometimes help clarify whether the change is likely to be significant, and the finding is generally not used alone to make major medical decisions until more evidence accumulates.
• When no answer is found, the raw sequencing data can often be reanalyzed periodically as scientific knowledge improves, since a change unrecognized today is regularly reclassified later; this is one of the practical advantages of whole genome sequencing, since the original data already covers virtually the whole genetic code and rarely needs to be regenerated from a new sample.
• When secondary findings were requested and identified, families are connected with the relevant specialists for that specific condition, separate from the original reason testing was pursued.

Whole genome sequencing is available in India through a small but growing number of accredited diagnostic and genetics laboratories, though it remains less widely available, and generally costlier with a longer turnaround time, than whole exome sequencing. The Indian Academy of Medical Genetics has published specific guidance for the use of sequencing-based testing in Indian clinical practice, describing whole exome sequencing as a reasonable first-tier test for conditions likely caused by a change within a single gene, while reserving whole genome sequencing for situations where whole exome sequencing has not provided an answer, or where a structural, non-coding, or repeat-expansion cause is specifically suspected. It also stresses that responsible use of this testing depends on early referral to a clinical geneticist, thorough counseling before testing that covers what the test can and cannot answer, and interpretation by laboratories with the training and quality standards needed to correctly classify what is often an especially large and complex set of results. Families considering this testing in India are encouraged to confirm that a laboratory holds appropriate accreditation, that genetic counseling is included both before and after testing as a standard part of the process, and to ask specifically whether testing will be performed as a trio with both parents, since this affects both the speed and the certainty with which results can be interpreted.

[Author]

Posts